LL-37: Benefits, Antimicrobial Mechanism, and Research Status (2026)
Most claims about LL-37 peptide benefits skip the one fact that makes this molecule unusual: LL-37 is not a designer research peptide at all, it is a fragment your own body already makes. It is the only cathelicidin found in humans, cut from a precursor protein called hCAP18 and encoded by the CAMP gene [1]. That endogenous origin is why researchers study it for wound repair, antimicrobial defense, and tissue regeneration, and also why the evidence is more mixed than the marketing suggests.
The Compound Universe Take: LL-37 is a natural human host-defense peptide studied mainly for wound healing, antimicrobial action, and angiogenesis. The strongest human signal is a small randomized trial of topical LL-37 on diabetic foot ulcers, where it sped granulation tissue formation [2]. Most other benefits rest on animal and cell studies, and LL-37 is not FDA-approved. It also has a documented double-edged side in psoriasis and cancer, so treat it as research-stage, not proven therapy.
New here? Start with the research on peptides studied for skin repair for the wider picture, then use this page for LL-37 specifically.
What LL-37 is: the only human cathelicidin
LL-37 is a 37-amino-acid peptide that starts with two leucine residues, which is where the “LL” name comes from. It is released when the hCAP18 precursor is cleaved by proteases such as proteinase 3 and kallikrein 5 [1].
Calling it an “antimicrobial peptide” undersells it. Because LL-37 does so many things beyond killing microbes, the literature usually labels it a host-defense peptide: it disrupts bacterial membranes, neutralizes bacterial endotoxin, recruits immune cells, and signals to skin and blood-vessel cells during repair [1].
| Class | Studied for | Evidence tier | Legal status (US) |
|---|---|---|---|
| Human cathelicidin (host-defense peptide) | Diabetic foot ulcer / wound healing | Human pilot (small RCT) | Not FDA-approved |
| Human cathelicidin | Angiogenesis, tissue repair | Animal + in-vitro | Not FDA-approved |
| Human cathelicidin | Antimicrobial, endotoxin neutralization | In-vitro / mechanistic | Research use only |
| Human cathelicidin | Immune modulation | In-vitro / mechanistic | Research use only |
LL-37 peptide benefits the research supports
The evidence sorts cleanly by how it was tested. One area has a human trial, one has strong animal data, and the rest is mechanistic lab work. Reading the benefits in that order keeps the claims honest.
Wound healing and diabetic foot ulcer repair (human pilot)
This is the most concrete result. A 2023 randomized, double-blind, placebo-controlled trial tested a topical LL-37 cream on diabetic foot ulcers in 25 patients [2]. The LL-37 group reached a full granulation index by day 14, while the placebo group took until day 28 (Human pilot). Granulation tissue is the new vascularized tissue that fills a wound, so faster granulation points to quicker repair.
The trial is small and single-center, so it is a promising signal rather than settled proof. It remains, however, the best human evidence attached to any LL-37 benefit.
Angiogenesis and tissue repair via FPRL1 (animal)
LL-37 acts as a pro-angiogenic factor, meaning it prompts the growth of new blood vessels that a healing wound needs. A foundational study showed LL-37 drives angiogenesis by activating the receptor FPRL1 on endothelial cells, and it improved new vessel formation in a rabbit model of hindlimb ischemia (Animal + in-vitro) [3].
Supporting work found LL-37 raises VEGF expression in human keratinocytes, linking the peptide to the vascular side of skin repair (In-vitro) [1]. Together these explain the mechanism behind the wound-healing result above.
Antimicrobial and endotoxin-neutralizing activity (in-vitro)
LL-37 is one of the most studied antimicrobial peptides. It perforates the membranes of Gram-positive and Gram-negative bacteria and can act against some enveloped viruses (In-vitro) [1].
It also does something subtler: LL-37 binds and inactivates bacterial lipopolysaccharide, the endotoxin that triggers runaway inflammation, which is part of why it is examined in sepsis and infected-wound models (In-vitro / animal) [1].
Immune modulation and inflammation (in-vitro)
Beyond direct killing, LL-37 recruits neutrophils and other immune cells to a site, promotes neutrophil extracellular trap formation, and can dampen certain inflammatory pathways depending on the cell type [1]. Its immune role is genuinely two-sided, pro-inflammatory in some contexts and anti-inflammatory in others (In-vitro).
How LL-37 works: mechanism of the cathelicidin peptide
The through-line is charge. LL-37 is a cationic, amphipathic peptide, so it is drawn to the negatively charged surfaces of bacterial membranes, where it inserts and forms pores. The same charged, flexible structure lets it bind host receptors like FPRL1 to trigger repair signaling [1][3].
Read this before the hype: LL-37 is not FDA-approved, and material sold to labs is labeled “for research use only.” This page summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. Legal status varies by jurisdiction and is changing.
| Mechanism | What it does | Evidence maturity | Regulatory status (US) |
|---|---|---|---|
| Membrane disruption | Perforates bacterial membranes; neutralizes LPS endotoxin | In-vitro / mechanistic | Not FDA-approved |
| FPRL1 activation | Stimulates endothelial migration and angiogenesis | Animal + in-vitro | Not FDA-approved |
| Keratinocyte signaling | Raises VEGF; supports granulation and re-epithelialization | Human pilot + animal | Investigational (topical) |
| Immune signaling | Chemotaxis, NET formation; dual pro / anti-inflammatory | In-vitro / mechanistic | Research use only |
The double-edged side: LL-37 in psoriasis and cancer research
An honest LL-37 summary cannot stop at benefits. The same peptide that aids repair is implicated in disease when it is overexpressed.
In psoriasis, LL-37 acts as an autoantigen and helps the immune system react to self-DNA, feeding the inflammation that drives the condition (Human / mechanistic) [4]. Its levels track with disease severity.
In cancer the picture is tissue-specific. Reviews report that LL-37 promotes progression in ovarian, lung, and breast cancers but suppresses growth in colon and gastric cancers (In-vitro / preclinical) [5]. The opposite effects trace to which receptors a given cell type expresses. This context-dependence is exactly why LL-37 is not a simple “more is better” molecule.
Key takeaways
- LL-37 is the only human cathelicidin, an endogenous host-defense peptide cut from the hCAP18 precursor and encoded by the CAMP gene [1].
- The strongest human evidence is a small randomized trial where topical LL-37 sped granulation in diabetic foot ulcers [2].
- LL-37 drives angiogenesis through the FPRL1 receptor, which underpins its wound-repair activity in animal models [3].
- Its antimicrobial and endotoxin-neutralizing actions are well documented in vitro but lack broad human trials [1].
- LL-37 is double-edged, linked to psoriasis autoimmunity and to both tumor promotion and suppression depending on tissue [4][5].
Frequently asked questions
What are the main LL-37 peptide benefits studied so far?
Research centers on wound healing, angiogenesis, and antimicrobial defense. The clearest human signal is faster granulation in a small diabetic foot ulcer trial [2], while most other benefits come from animal and cell studies.
Is LL-37 a natural peptide?
Yes. LL-37 is produced in the human body from the hCAP18 precursor and is the only cathelicidin humans make [1]. Research-grade LL-37 is a synthetic copy of that natural sequence.
Is LL-37 FDA-approved?
No. LL-37 is not FDA-approved for any use, and material sold to laboratories is labeled for research use only. A topical formulation has only been tested in small investigational trials.
How does LL-37 help wound healing?
It appears to promote new blood-vessel growth via the FPRL1 receptor and to raise VEGF in skin cells, supporting the granulation tissue a wound needs to close [2][3]. This is early-stage evidence, not an approved treatment.
Does LL-37 have risks?
The research flags real trade-offs. LL-37 is tied to psoriasis autoimmunity and can promote some cancers while suppressing others, so its effects are context-dependent rather than uniformly beneficial [4][5].
Is LL-37 the same as a designer peptide like BPC-157?
No. Both are studied for repair, but LL-37 is a natural human immune peptide, whereas others are synthetic sequences. Their mechanisms and evidence bases differ.
Interest in LL-37 sits where innate immunity meets tissue repair: the cathelicidin, released from hCAP18 by proteinase 3 and kallikrein 5, disrupts microbial membranes, neutralizes lipopolysaccharide, and signals through formyl peptide receptor-like 1 to raise VEGF and drive angiogenesis, while the same overexpression links it to psoriasis autoimmunity and to context-dependent roles across ovarian, lung, breast, colon, and gastric cancers; Compound Universe tracks LL-37 against the primary literature so the summary reflects evidence maturity rather than supplement marketing.
For readers weighing the science, the useful frame is proportion: the documented LL-37 peptide benefits are real in the lab and promising in one small human wound trial, but they sit beside genuine risks and a research-use-only legal status, which is why Compound Universe files LL-37 as an active area to watch rather than a settled therapy.
Compare next: research on immune support peptides | the Compound Universe peptide legality guide
References
- Svensson D, Nilsson B-O. Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update. Inflammation Research, 2025. PMID 40063262.
- Miranda E, et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Archives of Dermatological Research, 2023. PMID 37480520 / DOI 10.1007/s00403-023-02657-8.
- Koczulla R, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. Journal of Clinical Investigation, 2003;111(11):1665-72. PMID 12782669 / DOI 10.1172/JCI17545.
- Fuentes-Duculan J, et al. Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes. Experimental Dermatology, 2017;26(11):1075-1082. PMID 28482118.
- Piktel E, et al. The Role of Cathelicidin LL-37 in Cancer Development. Archivum Immunologiae et Therapiae Experimentalis, 2016;64(1):33-46. PMID 26395996.